Vanda Pharmaceuticals Inc. $VNDA Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC raised its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 11.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 3,759,559 shares of the biopharmaceutical company’s stock after purchasing an additional 378,598 shares during the period. Renaissance Technologies LLC owned 0.06% of Vanda Pharmaceuticals worth $25,979,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Torren Management LLC bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $25,000. Russell Investments Group Ltd. raised its stake in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 5,328 shares in the last quarter. Quarry LP acquired a new stake in Vanda Pharmaceuticals during the third quarter valued at approximately $53,000. Cerity Partners LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter worth approximately $69,000. Finally, Boothbay Fund Management LLC bought a new position in Vanda Pharmaceuticals during the 3rd quarter worth approximately $72,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $5.05 on Thursday. The company has a quick ratio of 2.15, a current ratio of 2.16 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $5.95 and its two-hundred day moving average price is $6.86. Vanda Pharmaceuticals Inc. has a 52-week low of $4.14 and a 52-week high of $9.94. The stock has a market capitalization of $303.66 million, a P/E ratio of -1.25 and a beta of 0.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.13). The company had revenue of $51.72 million for the quarter, compared to the consensus estimate of $54.98 million. Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%. As a group, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -2.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on VNDA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.30.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.